Company intelligence / Profile preview
Essen BioTech
Bahrainessen-biotech.com ↗
- Ownership
- Private
- Employees
- ~500
- Development stage
- Other
01
Overview
Developing immunotherapies with multiple Phase2 clinical programs including CAR-T therapies targeting hematologic cancers and glioma[3][4].
- Therapeutic areas
- OncologyImmunologyNeurology
- Modalities
- CAR-T Cell TherapyMSC Stem Cell TherapyNK Cell Immune TherapyCytotoxic T Lymphocytes (CTLs) TherapyDendritic Cell Vaccines (DCv)Gene Therapy
- Industry
- Biotech
02
Drug pipeline
19 assets18 more assets in the full pipeline.
03
Partnerships
Collaborationswithrenowneduniversitiesandhospitalsworldwide"(specificinstitutionsnotnamed)[1]
Beyond the preview
Go deeper on Essen BioTech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Essen BioTech.